HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

6th Edition of World Congress on Infectious Diseases

June 24-26, 2024 | Paris, France

June 24 -26, 2024 | Paris, France
Infection 2023

Kristina Cerniauskiene

Speaker at World Congress on Infectious Diseases 2023 - Kristina Cerniauskiene
Lithuanian University of Health Science, Lithuania
Title : Profile of beta-lactamases in multidrug-resistant (MDR) acinetobacter baumannii strains in lithuania 2016-2017 and 2021-2022 years


Introduction: Acinetobacter baumannii (A. baumannii) is an important nosocomial pathogen that possesses not only intrinsic resistance to many classes of antibiotics, but also has a propensity for rapid development of antimicrobial resistance during treatment.

Aims & Objectives: Aim of our study was to investigate A. baumannii strains producing different beta-lactamases. A total of 223 A. baumannii were isolated from different clinical samples of patients treated in 2016-2017 and 2021-2022 years in Hospital of Lithuanian University of Health Sciences. 

Methods: ESBL plus AmpC screen disc kit (Abtek Biologicals, UK) was used to determine the production of the extended spectrum β-lactamase (ESBL) and AmpC β-lactamase. Combination meropenem disc test was used to determine the co-production of KPC and MBL carbapenemases. For the statistical analysis were used Chi-square test and multivariate analysis; p <0.05 was considered statistically significant. 

Results: All isolates had a multidrug resistant profile, and all were resistant to the carbapenems but remained susceptible to colistin. Phenotypic method showed that 60.9% (n=142) of A. baumannii strains were AmpC β lactamase, 11.6% (n=27) ESBL and 76.8% (n=179) KPC β lactamase producers. 46.3% (n=108) of A. baumannii strains had AmpC plus KPC β lactamases, 2.6 % (n=6) AmpC plus ESBL, 2.6 % (n=6) ESBL plus KPC and 3.8% (n=9) AmpC plus KPC plus ESBL. 

All tested strains were divided into fourth groups: non producing β - lactamase (9.9%, n=23), producing only AmpC, KPC or ESBL (34.8%, n=81), producing two diferent β - lactamases: AmpC plus KPC, AmpC plus ESBL or ESBL plus KPC (51.5%, n=120) and the last group: producing all β - lactamases (3.9%, n=9). We have found that all A.baumannii strains were β - lactamase producers in 2021/2022 while 17.7% (n=23) strains didn’t produce any β - lactamase in 2016/2017. In 2016-2017 only one β - lactamase producing stains were detected in 62.3% of tested strains while in 2021-2022 no one only one β - lactamase producing strains were detected. A.baumannii strains producing two different β - lactamases were more frequently identified in 2021/2022 compared to 2016-2017 (94.2% (n=97) compared to (17.7% (n=23), p<0.001). ESBL, AmpC and KPC β - lactamase producing strains were identified 5.8 % (n=6) in 2021-2022 and only 1.3 % (n=3) in 2016-2017 (p<0,001). 

Conclusions: Increased synthesis of β - lactamases in 2021-2022 compared to 2016-2017 years is a serious warning because β - lactamases are a major threat to the effectiveness of antibiotics that are currently available for medical uses.

Audience Take Away:

  • Phenotypic methods for the detection of β - lactamases are easy and simple and can be implemented in routine diagnostic laboratories along with susceptibility testing. These data will assist the clinicians in the management and control of infections.


Dr. K. Cerniauskiene studied Kaunas Medical University, Lithuania and graduated as MS in 2010. She then studied in residency, obtained the qualification of laboratory medicine doctor at the Lithuanian University of Health Science in 2016. In the same year, she started working as a laboratory medicine doctor in the laboratory medicine clinic, microbiology laboratory. In 2017, she entered the doctoral studies program at the Lithuanian University of Health Sciences, the topic of her dissertation is the microbiological and molecular characteristics of Acinetobacter baumannii and its importance in clinical practice.